Entry Point Capital, LLC Autolus Therapeutics PLC Put Options Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding AUTL
# of Institutions
112Shares Held
156MCall Options Held
0Put Options Held
116K-
Wellington Management Group LLP Boston, MA25.3MShares$46.1 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$37.3 Million0.24% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$30.3 Million73.83% of portfolio
-
Deep Track Capital, LP Greenwich, CT14.2MShares$25.9 Million1.47% of portfolio
-
Avoro Capital Advisors LLC New York, NY9.91MShares$18 Million0.34% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $165M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...